Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Cervical stromal invasion predicting survival in endometrial cancer.

Ferriss JS, Brix W, Tambouret R, DeSimone CP, Stoler M, Modesitt SC.

Obstet Gynecol. 2010 Nov;116(5):1035-41. doi: 10.1097/AOG.0b013e3181f73fc2.

PMID:
20966686
2.

Stage II endometrioid adenocarcinoma of the endometrium: clinical implications of cervical stromal invasion.

Orezzoli JP, Sioletic S, Olawaiye A, Oliva E, del Carmen MG.

Gynecol Oncol. 2009 Jun;113(3):316-23. doi: 10.1016/j.ygyno.2009.03.007. Epub 2009 Apr 5.

PMID:
19345400
3.

The significance of the amount of myometrial invasion in patients with Stage IB endometrial carcinoma.

Alektiar KM, McKee A, Lin O, Venkatraman E, Zelefsky MJ, Mychalczak BR, McKee B, Hoskins WJ, Barakat RR.

Cancer. 2002 Jul 15;95(2):316-21.

4.

The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.

Cirisano FD Jr, Robboy SJ, Dodge RK, Bentley RC, Krigman HR, Synan IS, Soper JT, Clarke-Pearson DL.

Gynecol Oncol. 2000 Apr;77(1):55-65.

PMID:
10739691
5.

Are uterine risk factors more important than nodal status in predicting survival in endometrial cancer?

Kwon JS, Qiu F, Saskin R, Carey MS.

Obstet Gynecol. 2009 Oct;114(4):736-43. doi: 10.1097/AOG.0b013e3181b96ec6.

PMID:
19888029
6.

Lymphovascular invasion is a significant predictor for distant recurrence in patients with early-stage endometrial endometrioid adenocarcinoma.

Nofech-Mozes S, Ackerman I, Ghorab Z, Ismiil N, Thomas G, Covens A, Khalifa MA.

Am J Clin Pathol. 2008 Jun;129(6):912-7. doi: 10.1309/CP3HGX7H753QQU8T.

PMID:
18480008
7.

Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer?

Alektiar KM, McKee A, Lin O, Venkatraman E, Zelefsky MJ, McKee B, Hoskins WJ, Barakat RR.

Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):79-85.

PMID:
12182977
8.

An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.

Gadducci A, Cosio S, Fanucchi A, Cristofani R, Genazzani AR.

Anticancer Res. 2000 May-Jun;20(3B):1977-84.

PMID:
10928137
9.

[Multivariate analysis of prognostic factors in endometrial carcinoma].

Li B, Wu LY, Li SM, Zhang WH, Zhang R, Ma SK.

Ai Zheng. 2004 Sep;23(9):1085-8. Chinese.

PMID:
15363208
11.

Intravaginal brachytherapy alone for intermediate-risk endometrial cancer.

Alektiar KM, Venkatraman E, Chi DS, Barakat RR.

Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):111-7.

PMID:
15850910
12.

Clinical value of immunohistochemically detected lymphatic and vascular invasions in clinically staged endometrioid endometrial cancer.

Alexander-Sefre F, Nibbs R, Rafferty T, Ayhan A, Singh N, Jacobs I.

Int J Gynecol Cancer. 2009 Aug;19(6):1074-9. doi: 10.1111/IGC.0b013e3181abb0c0.

PMID:
19820371
13.

Lymph-vascular space involvement and outer one-third myometrial invasion are strong predictors of distant haematogeneous failures in patients with stage I-II endometrioid-type endometrial cancer.

Gadducci A, Cavazzana A, Cosio S, DI Cristofano C, Tana R, Fanucchi A, Teti G, Cristofani R, Genazzani AR.

Anticancer Res. 2009 May;29(5):1715-20.

14.

Uterine carcinosarcomas and grade 3 endometrioid cancers: evidence for distinct tumor behavior.

Bansal N, Herzog TJ, Seshan VE, Schiff PB, Burke WM, Cohen CJ, Wright JD.

Obstet Gynecol. 2008 Jul;112(1):64-70. doi: 10.1097/AOG.0b013e318176157c.

PMID:
18591309
15.

Preoperative cervical cytology in endometrial carcinoma and its clinicopathologic relevance.

Fukuda K, Mori M, Uchiyama M, Iwai K, Iwasaka T, Sugimori H, Yamasaki F.

Gynecol Oncol. 1999 Mar;72(3):273-7.

PMID:
10053095
16.

Diffusely infiltrative endometrial adenocarcinoma: an adenoma malignum pattern of myoinvasion.

Longacre TA, Hendrickson MR.

Am J Surg Pathol. 1999 Jan;23(1):69-78.

PMID:
9888705
17.

Endometrioid endometrial carcinoma with atrophic endometrium and poor prognosis.

Geels YP, Pijnenborg JM, van den Berg-van Erp SH, Bulten J, Visscher DW, Dowdy SC, Massuger LF.

Obstet Gynecol. 2012 Nov;120(5):1124-31. doi: http://10.1097/AOG.0b013e31825bc3b4.

PMID:
23090531
19.

Tumor size: a better independent predictor of distant failure and death than depth of myometrial invasion in International Federation of Gynecology and Obstetrics stage I endometrioid endometrial cancer.

Chattopadhyay S, Cross P, Nayar A, Galaal K, Naik R.

Int J Gynecol Cancer. 2013 May;23(4):690-7. doi: 10.1097/IGC.0b013e31828c85c6.

PMID:
23518862
20.

Assessment of the depth of myometrial invasion in stage I endometrioid endometrial cancer using pancytokeratin immunohistochemistry.

Alexander-Sefre F, Singh N, Ayhan A, Thomas JM, Jacobs IJ.

Int J Gynecol Cancer. 2004 Jul-Aug;14(4):665-72.

PMID:
15304163

Supplemental Content

Support Center